A Clinical Approach to Antioxidant Therapy: Hypertonic Fluid Resuscitation Trial

PDF

Authors
  1. Rotstein, O.S.
  2. Rhind, S.G.
Corporate Authors
Defence R&D Canada - Toronto, Toronto ONT (CAN);Toronto General Hospital, Toronto Ont (CAN) Department of Surgery
Abstract
It is well established that severe trauma with hemorrhagic shock produces significant immunomodulation, including enhanced PMN activation, adherence and emigration into tissues, along with the induction of inflammatory cytokine cascades, which collectively contribute to the systemic inflammatory response syndrome (SIRS), frequently culminating in acute respiratory distress syndrome (ARDS) and multiple organ dysfunction syndrome (MODS). The hemodynamic and physiological benefits of hypertonic saline / dextran solutions (HS/D) have been evaluated extensively in animal and human research, and efficacy has been suggested for the treatment of hemorrhagic shock. Work from our research group and others has substantiated that in comparison to large volume crystalloid resuscitation, small volume resuscitation with HS/D has the remarkable capacity to reduce potentially deleterious immunologic complications. However, human clinical studies evaluating the cellular and molecular immune consequences of small-volume HSD resuscitation are lacking; also there is need to investigate modified fluid formulations incorporating novel antiinflammatory agents such as the antioxidant N-acetylcysteine.

Il y a un résumé en français ici.

Keywords
Fluid resuscitation;Clinical human trials;Inflammatory response;Immune function;Cellular adhesion molecules;Blood loss
Report Number
DRDC-TORONTO-CR-2003-058 — Contractor Report
Date of publication
01 Jun 2003
Number of Pages
32
DSTKIM No
CA023175
CANDIS No
520376
Format(s):
Electronic Document(PDF);CD ROM

Permanent link

Document 1 of 1

Date modified: